| Characteristic | Number of clinical trials |
|---|---|
| β-amyloid mAb | 22 |
| Combination treatment | 8 |
| Stem cells | 7 |
| Anti-tau mAb | 7 |
| Dopamine Dâ‚‚ receptor partial agonist | 6 |
| Sigma1/2 receptor antagonist | 6 |
| Supplement/vitamin | 6 |
| SV2A protein modulator | 5 |
| ART | 4 |
| Vaccine | 4 |
| Cannabinoid | 4 |
| Other** | 30 |
The chart is not accessible to screen readers. Please switch to the table view to access the data.
Loading statistic...
Download
Source
Sources
Release date
February 2021
More information
Region
Worldwide
Survey time period
as of February 2021
Number of respondents
109*
Supplementary notes
* Technologies with at least 2 clinical trials ongoing.
** Other includes various technologies each with <4 clinical trials, including: APP inhibitor, TKIs, Omega-3 fatty acid, NMDA receptor antagonist, α-2 adrenergic receptor agonist, AAV gene therapy, Nicotinamide riboside, 18-kDa TSPO radioligand, AChE inhibitor, QC inhibitor, Interleukin inhibitors, HGF stimulants, and undefined.
Citation formats
